{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:29:16Z","timestamp":1787056156811,"version":"build-2736575974"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.actbio.2026.07.022","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:45:02Z","timestamp":1784097902000},"page":"42-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Emerging biomaterials deliver heat shock protein 90 inhibitors to enhance therapeutic efficacy in cancer therapy"],"prefix":"10.1016","volume":"221","author":[{"given":"Yujie","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanpeng","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1805-5061","authenticated-orcid":false,"given":"Zhigang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2026.07.022_bib0001","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.actbio.2026.07.022_bib0002","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41591-023-02655-3","article-title":"The landscape of cancer research and cancer care in china","volume":"29","author":"Lu","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.actbio.2026.07.022_bib0003","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/s41590-025-02308-2","article-title":"Cancer vaccines as enablers of immunotherapy","volume":"26","author":"Khleif","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0004","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.actbio.2026.07.022_bib0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2026.07.022_bib0006","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-024-01601-1","article-title":"Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies","volume":"17","author":"Zuo","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0007","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-023-01920-w","article-title":"Identification of HSP90b1 in pan-cancer hallmarks to aid development of a potential therapeutic target","volume":"23","author":"Huang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.actbio.2026.07.022_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231217976","article-title":"Phase ib study of HSP90 inhibitor, onalespib (at13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer","volume":"15","author":"Williams","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100888","article-title":"Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins","volume":"65","author":"Parma","year":"2022","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.actbio.2026.07.022_bib0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12943-020-01208-3","article-title":"Exosomal circSHKBP1 promotes gastric cancer progression via regulating the mir-582-3p\/HUR\/VEGF axis and suppressing HSP90 degradation","volume":"19","author":"Xie","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.actbio.2026.07.022_bib0011","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.2022019047","article-title":"Epichaperome inhibition targets TP53-mutant AML and AML stem\/progenitor cells","volume":"142","author":"Carter","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2026.07.022_bib0012","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1038\/s41587-024-02494-8","article-title":"Engineered platelets as targeted protein degraders and application to breast cancer models","volume":"43","author":"Chen","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0013","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1038\/s41418-025-01502-x","article-title":"Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition","volume":"32","author":"Isermann","year":"2025","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.actbio.2026.07.022_bib0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12013-024-01502-7","article-title":"Targeting HSP90 in gynecologic cancer: molecular mechanisms and therapeutic approaches","volume":"83","author":"Min","year":"2024","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.actbio.2026.07.022_bib0015","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41586-021-04252-1","article-title":"Structure of hsp90\u2013hsp70\u2013hop\u2013GR reveals the hsp90 client-loading mechanism","volume":"601","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2026.07.022_bib0016","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-021-04236-1","article-title":"Structure of hsp90\u2013p23\u2013GR reveals the hsp90 client-remodelling mechanism","volume":"601","author":"Noddings","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2026.07.022_bib0017","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jhep.2022.12.010","article-title":"Targeting proteostasis of the HEV replicase to combat infection in preclinical models","volume":"78","author":"Zhang","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0018","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41392-025-02166-2","article-title":"Advances in the structures, mechanisms and targeting of molecular chaperones","volume":"10","author":"Gu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.actbio.2026.07.022_bib0019","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1007\/s11030-025-11160-3","article-title":"Recent progress and structural insights of potential hsp90 inhibitors as anticancer agents","volume":"29","author":"Singh","year":"2025","journal-title":"Mol. Divers."},{"key":"10.1016\/j.actbio.2026.07.022_bib0020","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/s41565-025-02021-z","article-title":"Progress in cancer vaccines enabled by nanotechnology","volume":"20","author":"Kim","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202519222","article-title":"Innovative biomaterials synergize oncolytic virus for elevating tumor immunotherapy potency","volume":"38","author":"Wen","year":"2026","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0022","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1039\/D6CC00136J","article-title":"Engineered covalent organic framework-based nanosystem for strengthening pyroptosis-mediated tumor immunotherapy","volume":"62","author":"Wen","year":"2026","journal-title":"Chem. Commun."},{"key":"10.1016\/j.actbio.2026.07.022_bib0023","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.actbio.2026.07.022_bib0024","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.mattod.2025.06.011","article-title":"Sustainable cancer therapy","volume":"88","author":"Zhao","year":"2025","journal-title":"Mater. Today"},{"key":"10.1016\/j.actbio.2026.07.022_bib0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.actbio.2026.07.022_bib0026","doi-asserted-by":"crossref","first-page":"40184","DOI":"10.1021\/acsnano.5c16196","article-title":"Near-infrared-triggered photoresponsive nanobombs overcome tumor immunosuppression through coordinated pyroptosis activation and mitophagy blockade","volume":"19","author":"Zhang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.07.022_bib0027","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s43018-025-01025-x","article-title":"Nanotechnology for immuno-oncology","volume":"6","author":"Grippin","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.actbio.2026.07.022_bib0028","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41568-025-00847-2","article-title":"Advancing engineering design strategies for targeted cancer nanomedicine","volume":"25","author":"Gomerdinger","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2026.07.022_bib0029","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.actbio.2026.01.052","article-title":"Engineered acid-regulating liposomal nanovesicles for synergistic photodynamic pyroptosis and immunotherapy","volume":"213","author":"Chen","year":"2026","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0030","article-title":"Microenvironment responsive pod-structured astaxanthin nanocarrier for ameliorating inflammatory bowel disease","volume":"35","author":"Wang","year":"2024","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.actbio.2026.07.022_bib0031","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1021\/acs.jcim.5c00629","article-title":"Dual-site targeting by peptide inhibitors of the n-terminal domain of hsp90: mechanism and design","volume":"65","author":"Zang","year":"2025","journal-title":"J. Chem Inf. Model."},{"key":"10.1016\/j.actbio.2026.07.022_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106260","article-title":"Natural HSP90 inhibitors as a potential therapeutic intervention in treating cancers: a comprehensive review","volume":"181","author":"Liew","year":"2022","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.actbio.2026.07.022_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117925","article-title":"Optimization of an hsp90\u03b2-selective inhibitor via exploration of the hsp90 n-terminal ATP-binding pocket","volume":"297","author":"Serwetnyk","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0034","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2026.07.022_bib0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7150\/thno.63788","article-title":"A novel c-terminal heat shock protein 90 inhibitor that overcomes STAT3-wnt-\u03b2-catenin signaling-mediated drug resistance and adverse effects","volume":"12","author":"Lee","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.actbio.2026.07.022_bib0036","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.7150\/thno.93236","article-title":"The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer","volume":"14","author":"Park","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.actbio.2026.07.022_bib0037","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/cancers16030638","article-title":"The interplay between heat shock proteins and cancer pathogenesis: a novel strategy for cancer therapeutics","volume":"16","author":"Somu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.actbio.2026.07.022_bib0038","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1021\/acscentsci.2c00013","article-title":"Development of a first-in-class small-molecule inhibitor of the c-terminal hsp90 dimerization","volume":"8","author":"Bhatia","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.actbio.2026.07.022_bib0039","doi-asserted-by":"crossref","first-page":"17946","DOI":"10.1021\/acs.jmedchem.4c01048","article-title":"Geldanamycin, a naturally occurring inhibitor of hsp90 and a lead compound for medicinal chemistry","volume":"67","author":"Kitson","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0040","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.apsb.2020.11.015","article-title":"The disruption of protein\u2212protein interactions with co-chaperones and client substrates as a strategy towards hsp90 inhibition","volume":"11","author":"Serwetnyk","year":"2021","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.actbio.2026.07.022_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2017.07.021","article-title":"Synergistic anti-tumor effect of 17AAG with the PI3k\/mTOR inhibitor NVP-BEZ235 on human melanoma","volume":"406","author":"Calero","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.actbio.2026.07.022_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2021.131927","article-title":"Synthesis of novel geldanamycin derivatives","volume":"82","author":"Kitson","year":"2021","journal-title":"Tetrahedron"},{"key":"10.1016\/j.actbio.2026.07.022_bib0043","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/1568026615666150112113627","article-title":"Nayarisseri, Multiclass comparative virtual screening to identify novel hsp90 inhibitors: a therapeutic breast cancer drug target","volume":"15","author":"Dunna","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2024.101757","article-title":"In-silico identification of 3,4-diarylpyrazoles-based small molecules as potential hsp90 inhibitors","volume":"11","author":"Aboalroub","year":"2024","journal-title":"Results Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejmech.2017.04.019","article-title":"Design and synthesis of neolamellarin a derivatives targeting heat shock protein 90","volume":"135","author":"Jiang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0046","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/1878-0261.12054","article-title":"Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors","volume":"11","author":"Chai","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0047","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.2147\/OTT.S130236","article-title":"NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo","volume":"10","author":"Lian","year":"2017","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.actbio.2026.07.022_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114918","article-title":"Ganetespib (STA-9090) augments sorafenib efficacy via necroptosis induction in hepatocellular carcinoma: implications from preclinical data for a novel therapeutic approach","volume":"164","author":"Saber","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.actbio.2026.07.022_bib0049","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-18-0703","article-title":"Consecutive day HSP90 inhibitor administration improves efficacy in murine models of KIT-driven malignancies and canine mast cell tumors","volume":"24","author":"London","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2026.07.022_bib0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1078-0432.CCR-14-0979","article-title":"First-in-human phase i dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, at13387, in patients with advanced solid tumors","volume":"21","author":"Shapiro","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2026.07.022_bib0051","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3892\/or.2014.3552","article-title":"Comparative effects of SNX-7081 and SNX-2112 on cell cycle, apoptosis and hsp90 client proteins in human cancer cells","volume":"33","author":"Wang","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.actbio.2026.07.022_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118278","article-title":"Novel furanone-based anticancer agents: design, synthesis, hsp90 inhibition, in vivo antitumor activity and pharmacokinetic studies","volume":"302","author":"Tageldin","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0053","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13046-022-02416-z","article-title":"Inhibition of HSP 90 is associated with potent anti-tumor activity in papillary renal cell carcinoma","volume":"41","author":"Pahwa","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2026.07.022_bib0054","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1158\/1078-0432.CCR-21-1929","article-title":"TAS-116 (pimitespib), an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: an open-label, dose-finding, and expansion phase ib trial (EPOC1704)","volume":"27","author":"Kawazoe","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2026.07.022_bib0055","doi-asserted-by":"crossref","first-page":"9886","DOI":"10.1021\/acs.jmedchem.4c02182","article-title":"Structural optimization of pyrazole compounds as hsp90 regulators with enhanced antitumor activity","volume":"68","author":"Feng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0056","doi-asserted-by":"crossref","first-page":"19933","DOI":"10.1021\/acs.jmedchem.5c00409","article-title":"HSP90 mediates targeted degradation of nonclient protein PARP1 for breast cancer treatment","volume":"68","author":"Liu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0057","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/acs.jmedchem.9b00940","article-title":"Heat shock protein 90 inhibitors: an update on achievements, challenges, and future directions","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0058","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41467-021-21258-5","article-title":"EGCG binds intrinsically disordered n-terminal domain of p53 and disrupts p53-MDM2 interaction","volume":"12","author":"Zhao","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2026.07.022_bib0059","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-20-0304","article-title":"Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.actbio.2026.07.022_bib0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41586-022-04427-4","article-title":"The lung microbiome regulates brain autoimmunity","volume":"603","author":"Hosang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2026.07.022_bib0061","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1097\/j.pain.0000000000001886","article-title":"Heat shock protein 90 inhibitors block the antinociceptive effects of opioids in mouse chemotherapy-induced neuropathy and cancer bone pain models","volume":"161","author":"Stine","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.actbio.2026.07.022_bib0062","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaz1854","article-title":"Inhibition of hsp90 in the spinal cord enhances the antinociceptive effects of morphine by activating an ERK-RSK pathway","volume":"13","author":"Duron","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.actbio.2026.07.022_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104921","article-title":"Curcumin: an inflammasome silencer","volume":"159","author":"Hasanzadeh","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.actbio.2026.07.022_bib0064","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/biof.1776","article-title":"Targeting of the tumor microenvironment by curcumin","volume":"47","author":"Fu","year":"2021","journal-title":"Biofactors"},{"key":"10.1016\/j.actbio.2026.07.022_bib0065","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/10717544.2020.1785051","article-title":"Enhanced anti-hepatoma effect of a novel curcumin analog c086 via solid dispersion technology","volume":"27","author":"Deng","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.actbio.2026.07.022_bib0066","doi-asserted-by":"crossref","DOI":"10.1080\/13510002.2025.2493556","article-title":"Rotenone inhibited osteosarcoma metastasis by modulating ZO-2 expression and location via the ROS\/ca2+ \/AMPK pathway","volume":"30","author":"Ma","year":"2025","journal-title":"Redox Rep."},{"key":"10.1016\/j.actbio.2026.07.022_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2021.132982","article-title":"Rotenone impairs learning and memory in mice through microglia-mediated blood brain barrier disruption and neuronal apoptosis","volume":"291","author":"Guo","year":"2022","journal-title":"Chemosphere"},{"key":"10.1016\/j.actbio.2026.07.022_bib0068","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1002\/ptr.8347","article-title":"Silybin: a review of its targeted and novel agents for treating liver diseases based on pathogenesis","volume":"38","author":"Wu","year":"2024","journal-title":"Phytother. Res."},{"key":"10.1016\/j.actbio.2026.07.022_bib0069","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1093\/nar\/gkw246","article-title":"Insights into RNA binding by the anticancer drug cisplatin from the crystal structure of cisplatin-modified ribosome","volume":"44","author":"Melnikov","year":"2016","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.actbio.2026.07.022_bib0070","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.neo.2017.08.002","article-title":"Chk1 inhibitor SCH900776 effectively potentiates the cytotoxic effects of platinum-based chemotherapeutic drugs in human colon cancer cells","volume":"19","author":"Her\u016fdkov\u00e1","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.actbio.2026.07.022_bib0071","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cbi.2016.04.011","article-title":"Targeting HSP90\/survivin using a cell permeable structure based peptido-mimetic shepherdin in retinoblastoma","volume":"252","author":"Venkatesan","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.actbio.2026.07.022_bib0072","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3390\/cells11182778","article-title":"Targeting HSP90 as a novel therapy for cancer: mechanistic insights and translational relevance","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.actbio.2026.07.022_bib0073","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41401-023-01184-6","article-title":"Author correction: DCZ5248, a novel dual inhibitor of hsp90 and autophagy, exerts antitumor activity against colon cancer","volume":"45","author":"Chen","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.actbio.2026.07.022_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e29367","article-title":"Gkongensin a, an HSP90beta inhibitor, improves hyperlipidemia, hepatic steatosis, and insulin resistance","volume":"10","author":"Miao","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.actbio.2026.07.022_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108308","article-title":"Enniatin a inhibits the chaperone hsp90 and unleashes the immune system against triple-negative breast cancer","volume":"26","author":"Eisa","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.actbio.2026.07.022_bib0076","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-025-02444-z","article-title":"In vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.actbio.2026.07.022_bib0077","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/17568919.2026.2619466","article-title":"Emerging roles of PARP-1 driven dual inhibitors in cancer therapy: SAR-guided strategies and synthetic lethality","volume":"18","author":"Dhir","year":"2026","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0078","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41467-017-02013-1","article-title":"Structure-guided design of an hsp90\u03b2 n-terminal isoform-selective inhibitor","volume":"9","author":"Khandelwal","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2026.07.022_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108396","article-title":"Following the design path of isoform-selective hsp90 inhibitors: small differences, great opportunities","volume":"245","author":"Dernov\u0161ek","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.actbio.2026.07.022_bib0080","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1007\/s11030-023-10795-4","article-title":"Assessment of structural and activity-related contributions of various PIM-1 kinase inhibitors in the treatment of leukemia and prostate cancer","volume":"29","author":"Sharma","year":"2025","journal-title":"Mol. Divers."},{"key":"10.1016\/j.actbio.2026.07.022_bib0081","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2174\/0115680266378477250610122156","article-title":"A review on anticancer potential and structure-activity relationships (SAR) of novel EGFR \/HER2 inhibitors","volume":"26","author":"Maity","year":"2025","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0082","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.7150\/thno.57828","article-title":"Recent progress in nanomedicine for enhanced cancer chemotherapy","volume":"11","author":"Wei","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.actbio.2026.07.022_bib0083","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.actbio.2026.07.022_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119920","article-title":"Stimuli-responsive phospholipid-drug conjugates (PDCs)-based nanovesicles for drug delivery and theranostics","volume":"590","author":"Yu","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2026.07.022_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119882","article-title":"Redox-sensitive nanoscale drug delivery systems for cancer treatment","volume":"589","author":"Mirhadi","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2026.07.022_bib0086","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2020.08.012","article-title":"Controlled anti-cancer drug release through advanced nano-drug delivery systems: static and dynamic targeting strategies","volume":"327","author":"Kashkooli","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2026.07.022_bib0087","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.addr.2021.01.019","article-title":"Overcoming barriers by local drug delivery with liposomes","volume":"174","author":"Antimisiaris","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2026.07.022_bib0088","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2015.12.053","article-title":"Formulation and in vitro efficacy of liposomes containing the hsp90 inhibitor 6BrCaQ in prostate cancer cells","volume":"499","author":"Sauvage","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2026.07.022_bib0089","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90585-w","article-title":"Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro","volume":"11","author":"Epp-Ducharme","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2026.07.022_bib0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14686996.2022.2052181","article-title":"The emergence of nanoporous materials in lung cancer therapy","volume":"23","author":"Radhakrishnan","year":"2022","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0091","doi-asserted-by":"crossref","first-page":"14349","DOI":"10.1021\/acs.chemrev.1c00236","article-title":"Interfacial assembly and applications of functional mesoporous materials","volume":"121","author":"Duan","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.actbio.2026.07.022_bib0092","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1039\/D4CS01308E","article-title":"Emerging compositions in functional mesoporous materials","volume":"54","author":"He","year":"2025","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.actbio.2026.07.022_bib0093","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jre.2021.09.022","article-title":"Tumor\u2013microenvironment activated programmable synergistic cancer therapy by bioresponsive rare-earth nanocomposite","volume":"40","author":"Jia","year":"2022","journal-title":"J. Rare Earths"},{"key":"10.1016\/j.actbio.2026.07.022_bib0094","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1021\/acs.analchem.7b05295","article-title":"Preparation of microkernel-based mesoporous (SiO2 \u2013CdTe\u2013SiO2)@SiO2 fluorescent nanoparticles for imaging screening and enrichment of heat shock protein 90 inhibitors fromtripterygium wilfordii","volume":"90","author":"Hu","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.158624","article-title":"Biomineralization-inspired functional biomaterials: from principles to practice","volume":"504","author":"Hu","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.actbio.2026.07.022_bib0096","first-page":"165","article-title":"Expanding from materials to biology inspired by biomineralization","volume":"3","author":"Wang","year":"2024","journal-title":"Interdiscip. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0097","doi-asserted-by":"crossref","first-page":"30383","DOI":"10.1021\/acsnano.5c09597","article-title":"Biomineralized albumin-macrocyclic conjugates for synergistic metal ion-based combination therapy in cancer treatment","volume":"19","author":"Zhang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.07.022_bib0098","article-title":"Research progress and prospects for polymeric nanovesicles in anticancer drug delivery","volume":"10","author":"Li","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0099","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2531210","article-title":"Ginger-derived vesicle-like nanoparticles loaded with curcumin to alleviate ionizing radiation-induced intestinal damage via gut microbiota regulation","volume":"17","author":"Zhang","year":"2025","journal-title":"Gut. Microbes"},{"key":"10.1016\/j.actbio.2026.07.022_bib0100","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1039\/C5CS00199D","article-title":"Stimuli-responsive nanogel composites and their application in nanomedicine","volume":"44","author":"Molina","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.actbio.2026.07.022_bib0101","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2015.10.004","article-title":"Current advances in self-assembled nanogel delivery systems for immunotherapy","volume":"95","author":"Tahara","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2026.07.022_bib0102","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1039\/D2CS00247G","article-title":"Bioengineered nanogels for cancer immunotherapy","volume":"51","author":"Ma","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.actbio.2026.07.022_bib0103","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodhyd.2023.109439","article-title":"Remodeling the structure of soy protein fibrils to hydrogels for co-encapsulation of (\u2212)-epigallocatechin gallate (EGCG) and curcumin: role of EGCG","volume":"147","author":"Ji","year":"2024","journal-title":"Food Hydrocoll."},{"key":"10.1016\/j.actbio.2026.07.022_bib0104","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12943-025-02410-x","article-title":"PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy","volume":"24","author":"Kesharwani","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.actbio.2026.07.022_bib0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ecco-jcc\/jjz113","article-title":"Oral targeted delivery by nanoparticles enhances efficacy of an hsp90 inhibitor by reducing systemic exposure in murine models of colitis and colitis-associated cancer","volume":"14","author":"Yang","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.actbio.2026.07.022_bib0106","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202103936","article-title":"Tumor diagnosis and therapy mediated by metal phosphorus-based nanomaterials","volume":"33","author":"Liu","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0107","article-title":"Immunity-modulating metal-based nanomaterials for cancer immunotherapy","volume":"35","author":"Sun","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0108","doi-asserted-by":"crossref","DOI":"10.1002\/ppsc.201900124","article-title":"Tumor-targeting w18o49 nanoparticles for dual-modality imaging and guided heat-shock-response-inhibited photothermal therapy in gastric cancer","volume":"36","author":"Yang","year":"2019","journal-title":"Part. Part. Syst. Charact."},{"key":"10.1016\/j.actbio.2026.07.022_bib0109","article-title":"Inhibition of heat shock protein 90\u03b2 by catalpol: a potential therapeutic approach for alleviating inflammation-induced cartilage injuries in osteoarthritis","volume":"12","author":"Zhou","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.actbio.2026.07.022_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106140","article-title":"Curcumin dispersed with colloidal nano-particles inhibits enteric viruses replication","volume":"237","author":"Przybylski","year":"2025","journal-title":"Antiviral. Res."},{"key":"10.1016\/j.actbio.2026.07.022_bib0111","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1021\/acsptsci.4c00524","article-title":"Cell membrane hybrid liposome-targeted delivery of the heat shock protein 90 c-terminal inhibitor for the treatment of idiopathic pulmonary fibrosis","volume":"7","author":"Yang","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.actbio.2026.07.022_bib0112","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cstres.2024.08.002","article-title":"Previously unrecognized and potentially consequential challenges facing hsp90 inhibitors in cancer clinical trials","volume":"29","author":"Chang","year":"2024","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.actbio.2026.07.022_bib0113","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02559-5","article-title":"Targeting HSP90 in cancer: advances in the development of inhibitors, mechanisms of action, and therapeutic applications","volume":"25","author":"Wang","year":"2026","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.actbio.2026.07.022_bib0114","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1158\/1535-7163.MCT-24-1173","article-title":"Dual inhibitors of KRASG12d and HSP90 are effective against KRASG12d inhibitor resistance","volume":"25","author":"Pulido","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.actbio.2026.07.022_bib0115","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.1021\/acsami.8b22336","article-title":"Facile engineering of indomethacin-induced paclitaxel nanocrystal aggregates as carrier-free nanomedicine with improved synergetic antitumor activity","volume":"11","author":"Zhang","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2026.07.022_bib0116","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1021\/acsnano.9b02149","article-title":"Core-shell distinct nanodrug showing on-demand sequential drug release to act on multiple cell types for synergistic anticancer therapy","volume":"13","author":"Huang","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.07.022_bib0117","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.3892\/ol.2016.5192","article-title":"Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells","volume":"12","author":"Liu","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.actbio.2026.07.022_bib0118","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12943-023-01790-2","article-title":"Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases","volume":"22","author":"Wang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.actbio.2026.07.022_bib0119","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.155781","article-title":"Carrier-free multifunctional nanomedicine for enhanced hyperthermic intraperitoneal chemotherapy against abdominal pelvic tumors","volume":"498","author":"Fang","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.actbio.2026.07.022_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.143266","article-title":"HSP90 inhibitor-loaded hollow mesoporous nanoparticles for enhanced synergistic mild photothermal\/chemotherapy in triple negative breast cancer","volume":"310","author":"Yuan","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2021.134352","article-title":"Hsp90 co-chaperone degradation combined with antioxidation nanostrategy to rescue tauopathy-induced alzheimer\u2019s disease","volume":"432","author":"Tang","year":"2022","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.actbio.2026.07.022_bib0122","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.150526","article-title":"Transforming enemy into friend\u201d strategy-based stimuli responsive dual-drug liposomes for synergistic chemo-photodynamic therapy","volume":"487","author":"Yu","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.actbio.2026.07.022_bib0123","article-title":"Photothermal nanomaterials for theranostics of atherosclerosis and thrombosis","volume":"35","author":"Vazquez-Prada","year":"2023","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.actbio.2026.07.022_bib0124","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.7150\/thno.14882","article-title":"HSP90 inhibitor encapsulated photo-theranostic nanoparticles for synergistic combination cancer therapy","volume":"6","author":"Lin","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.actbio.2026.07.022_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101363","article-title":"NIR-triggered dual sensitization of nanoparticles for mild tumor phototherapy","volume":"42","author":"Liu","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.actbio.2026.07.022_bib0126","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1007\/s12274-021-3946-2","article-title":"Inspired heat shock protein alleviating prodrug enforces immunogenic photodynamic therapy by eliciting pyroptosis","volume":"15","author":"Zhou","year":"2022","journal-title":"Nano Res."},{"key":"10.1016\/j.actbio.2026.07.022_bib0127","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.carbon.2019.10.105","article-title":"Graphene oxide \/BaHoF5 \/ PEG nanocomposite for dual-modal imaging and heat shock protein inhibitor-sensitized tumor photothermal therapy","volume":"158","author":"Chang","year":"2020","journal-title":"Carbon"},{"key":"10.1016\/j.actbio.2026.07.022_bib0128","article-title":"Near infrared-triggered theranostic nanoplatform with controlled release of HSP90 inhibitor for synergistic mild photothermal and enhanced nanocatalytic therapy with hypoxia relief","volume":"18","author":"Tian","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.actbio.2026.07.022_bib0129","article-title":"Blockage of HSP90 and IDO1 pathway by \u03b1-MSH modified nanoelicitor to dual-facilitate mild photothermal therapy","volume":"1","author":"Fu","year":"2023","journal-title":"Pharm. Sci. Adv."},{"key":"10.1016\/j.actbio.2026.07.022_bib0130","first-page":"63","article-title":"Near-infrared light triggered multi-hit therapeutic nanosystem for tumor specific photothermal effect amplified signal pathway regulation and ferroptosis","volume":"9","author":"Lian","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0131","article-title":"Icaritin represses autophagy to promote colorectal cancer cell apoptosis and sensitized low-temperature photothermal therapy via targeting HSP90-TXNDC9 interactions","volume":"12","author":"He","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.actbio.2026.07.022_bib0132","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2020.12.028","article-title":"Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer","volume":"500","author":"Zhang","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.actbio.2026.07.022_bib0133","article-title":"Curcumin-enhanced NIR-II-responsive gold nanobipyramids for targeted HSP 90 inhibition","volume":"31","author":"Diao","year":"2025","journal-title":"Mater. Today Bio."},{"key":"10.1016\/j.actbio.2026.07.022_bib0134","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12951-021-01037-6","article-title":"Molecularly engineered carrier-free co-delivery nanoassembly for self-sensitized photothermal cancer therapy","volume":"19","author":"Shan","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.actbio.2026.07.022_bib0135","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.actbio.2022.06.011","article-title":"Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals","volume":"148","author":"Li","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0136","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbcan.2019.01.002","article-title":"Combination therapies with HSP90 inhibitors against colorectal cancer","volume":"1871","author":"Kryeziu","year":"2019","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"10.1016\/j.actbio.2026.07.022_bib0137","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.actbio.2024.11.035","article-title":"Thermo-responsive gold nanorod vesicles for combined NIR-II photothermal therapy and chemotherapy of solid tumors","volume":"192","author":"Xing","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0138","first-page":"20908","article-title":"Cancer cell-mimicking prussian blue nanoplatform for synergistic mild photothermal\/chemotherapy via heat shock protein inhibition","volume":"16","author":"Wang","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2026.07.022_bib0139","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202300945","article-title":"Stimulus-detonated biomimetic \u201cnanobomb\u201d with controlled release of HSP90 inhibitor to disrupt mitochondrial function for synergistic gas and photothermal therapy","volume":"12","author":"Yang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0140","doi-asserted-by":"crossref","first-page":"17688","DOI":"10.1021\/acsanm.4c02918","article-title":"Nanoscale gambogic acid liposomes for NIR-II photoacoustic imaging and photothermal-chemo tumor therapy","volume":"7","author":"Yang","year":"2024","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0141","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.1021\/acsnano.3c00891","article-title":"Photodynamic and photothermal therapies: synergy opportunities for nanomedicine","volume":"17","author":"Overchuk","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.07.022_bib0142","doi-asserted-by":"crossref","first-page":"7753","DOI":"10.1039\/D5TB00071H","article-title":"Suppression of the HSP90-HIF1\u03b1 pathway with SNX2112-encapsulated nano-micelles for effective triple-negative breast cancer photothermal combined photodynamic therapy","volume":"13","author":"Zhang","year":"2025","journal-title":"J. Mat. Chem. B"},{"key":"10.1016\/j.actbio.2026.07.022_bib0143","doi-asserted-by":"crossref","first-page":"25788","DOI":"10.1021\/acsami.4c03484","article-title":"GSH-responsive liposomes with heat shock protein regulatory ability for efficient photodynamic\/photothermal combined therapy of tumors","volume":"16","author":"Deng","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2026.07.022_bib0144","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jcis.2021.01.052","article-title":"Assembly of multifunction dyes and heat shock protein 90 inhibitor coupled to bovine serum albumin in nanoparticles for multimodal photodynamic\/photothermal\/chemo-therapy","volume":"590","author":"Wen","year":"2021","journal-title":"J. Colloid. Interface. Sci."},{"key":"10.1016\/j.actbio.2026.07.022_bib0145","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202419673","article-title":"Engineered nanozymes with asymmetric mn-o-ce sites for intratumorally leveraged multimode therapy","volume":"37","author":"Ye","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0146","doi-asserted-by":"crossref","first-page":"54207","DOI":"10.1021\/acsami.3c06535","article-title":"Manganese dioxide\/gold-based active tumor targeting nanoprobes for enhancing photodynamic and low-temperature-photothermal combination therapy in lung cancer","volume":"15","author":"Liu","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2026.07.022_bib0147","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1182\/blood-2018-99-120362","article-title":"Therapeutic targeting of HSP90 in AML and ALL","volume":"132","author":"Bhatia","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2026.07.022_bib0148","article-title":"HSP90 inhibitors and cancer: prospects for use in targeted therapies (review)","volume":"49","author":"Li","year":"2023","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.actbio.2026.07.022_bib0149","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121272","article-title":"Antibody-drug conjugate and free geldanamycin combination therapy enhances anti-cancer efficacy","volume":"610","author":"McCombs","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2026.07.022_bib0150","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2147\/IJN.S275805","article-title":"Hybrid nanoparticles modified by hyaluronic acid loading an HSP90 inhibitor as a novel delivery system for subcutaneous and orthotopic colon cancer therapy","volume":"16","author":"Pan","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.actbio.2026.07.022_bib0151","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202205550","article-title":"Inhibiting stress-activated signals to reverse heat resistance for augmented photothermal therapy based on biologically derived nanotherapeutics","volume":"32","author":"Luo","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0152","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12951-024-02460-1","article-title":"Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer","volume":"22","author":"Jia","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.actbio.2026.07.022_bib0153","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.157031","article-title":"Exploration and application of treating OSCC by a precisely concentrated synergistic agent in combination with thermally responsive release of effective therapeutic dosages of cisplatin","volume":"500","author":"Guo","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.actbio.2026.07.022_bib0154","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120817","article-title":"Targeted delivery of heat shock protein 90 inhibitors prevents growth of HER2-positive tumor","volume":"273","author":"Lim","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2026.07.022_bib0155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.actbio.2026.07.022_bib0156","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","article-title":"Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities","volume":"21","author":"Kim","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2026.07.022_bib0157","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","article-title":"Beyond immune checkpoint blockade: emerging immunological strategies","volume":"20","author":"Kubli","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2026.07.022_bib0158","article-title":"A poly-prodrug nanosphere for modulating janus-faced nature of pyroptosis to launch an immune offensive and defensive warfare reigniting the cancer-immunity cycle","volume":"35","author":"Han","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0159","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202402809","article-title":"Neighboring effect-initiated supramolecular nanocomplex with sequential infiltration as irreversible apoptosis inducer for synergetic chemo-immunotherapy","volume":"11","author":"Ye","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.actbio.2026.07.022_bib0160","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.actbio.2026.07.022_bib0161","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202408511","article-title":"Biomimetic nanomodulators with synergism of photothermal therapy and vessel normalization for boosting potent anticancer immunity","volume":"36","author":"Lan","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0162","doi-asserted-by":"crossref","first-page":"15055","DOI":"10.1021\/acsnano.5c01842","article-title":"Amplifying the immune activity of metal ions through metal\u2013phenolic complexation","volume":"19","author":"Wang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.07.022_bib0163","article-title":"Expanded ROS generation and hypoxia reversal: excipient-free self-assembled nanotheranostics for enhanced cancer photodynamic immunotherapy","volume":"36","author":"Yang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0164","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.7150\/thno.106758","article-title":"CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances t-cell immunity in murine b-cell malignancies","volume":"15","author":"Qin","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.actbio.2026.07.022_bib0165","doi-asserted-by":"crossref","first-page":"17145","DOI":"10.1021\/acsnano.4c03887","article-title":"Enhancing magnetic hyperthermia efficacy through targeted heat shock protein 90 inhibition: unveiling immune-mediated therapeutic synergy in glioma treatment","volume":"18","author":"Gupta","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.07.022_bib0166","article-title":"Multiple treatment of triple-negative breast cancer through gambogic acid-loaded mesoporous polydopamine","volume":"20","author":"Liu","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.actbio.2026.07.022_bib0167","article-title":"Hypoxia-responsive covalent organic framework nanoplatform for breast-cancer-targeted cocktail immunotherapy via triple therapeutic switch mechanisms","volume":"21","author":"Huang","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.actbio.2026.07.022_bib0168","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2020.04.040","article-title":"Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer","volume":"323","author":"Liu","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2026.07.022_bib0169","doi-asserted-by":"crossref","first-page":"11614","DOI":"10.1039\/D1CS00427A","article-title":"Magnetic nanoparticles and clusters for magnetic hyperthermia: optimizing their heat performance and developing combinatorial therapies to tackle cancer","volume":"50","author":"Gavil\u00e1n","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.actbio.2026.07.022_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2025.216575","article-title":"Magnetic hyperthermia mediated multimodal therapy for tumors: construction and potential applications of iron-based nanoplatforms","volume":"535","author":"Wang","year":"2025","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.actbio.2026.07.022_bib0171","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.biomaterials.2016.11.008","article-title":"Magnetic hyperthermia enhances cell toxicity with respect to exogenous heating","volume":"114","author":"Sanz","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2026.07.022_bib0172","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201900160","article-title":"Multifunctional magnetic nanoplatform eliminates cancer stem cells via inhibiting the secretion of extracellular heat shock protein 90","volume":"8","author":"Liu","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0173","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.acra.2023.08.006","article-title":"Distilling knowledge from an ensemble of vision transformers for improved classification of breast ultrasound","volume":"31","author":"Zhou","year":"2024","journal-title":"Acad. Radiol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0174","article-title":"High intensity focused ultrasound-driven nanomotor for effective ferroptosis-immunotherapy of TNBC","volume":"11","author":"Yu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.actbio.2026.07.022_bib0175","doi-asserted-by":"crossref","first-page":"18412","DOI":"10.1021\/acsnano.4c02921","article-title":"Hypoxia-specific metal\u2013organic frameworks augment cancer immunotherapy of high-intensity focused ultrasound","volume":"18","author":"Li","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.07.022_bib0176","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108393","article-title":"Immunomodulation and targeted drug delivery with high intensity focused ultrasound (HIFU): principles and mechanisms","volume":"244","author":"Ashar","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.actbio.2026.07.022_bib0177","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc1591","article-title":"High-intensity focused ultrasound in the treatment of solid tumours","volume":"5","author":"Kennedy","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2026.07.022_bib0178","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s10439-021-02833-9","article-title":"High-intensity focused ultrasound: a review of mechanisms and clinical applications","volume":"49","author":"Bachu","year":"2021","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.actbio.2026.07.022_bib0179","article-title":"Gambogic acid based coordination polymer reinforces high-intensity focused ultrasound treatment of gynecologic malignancies","volume":"37","author":"Zhang","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0180","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12272-024-01494-1","article-title":"Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress","volume":"47","author":"Liu","year":"2024","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.actbio.2026.07.022_bib0181","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-cancerbio-030518-055533","article-title":"HSP90: enabler of cancer adaptation","volume":"3","author":"Jaeger","year":"2019","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0182","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cstres.2024.05.005","article-title":"An update on the status of HSP90 inhibitors in cancer clinical trials","volume":"29","author":"Rastogi","year":"2024","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.actbio.2026.07.022_bib0183","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/17568919.2026.2642671","article-title":"Rational design and biological investigation of benzylidene-substituted pyrazolo[3,4- b]pyridine derivatives as novel PIM-1 kinase inhibitors with anticancer potential","volume":"18","author":"Singh","year":"2026","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0184","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107747","article-title":"Assay design and development strategies for finding hsp90 inhibitors and their role in human diseases","volume":"221","author":"Banerjee","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.actbio.2026.07.022_bib0185","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/17568919.2026.2658435","article-title":"Novel pyrimidine-triazole conjugates for targeted inhibition of EGFR: synthesis and biological evaluation","volume":"18","author":"Maity","year":"2026","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.actbio.2026.07.022_bib0186","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1021\/acschembio.6c00125","article-title":"Cell-impermeable hsp90\u03b1-selective inhibitor NDNA4 inhibits cancer cell migration and targets extracellular hsp90\u03b1\u2019s critical f-5 fragment","volume":"21","author":"Reynolds","year":"2026","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.actbio.2026.07.022_bib0187","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1021\/ja511893n","article-title":"Development of a mitochondria-targeted hsp90 inhibitor based on the crystal structures of human TRAP1","volume":"137","author":"Lee","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.actbio.2026.07.022_bib0188","doi-asserted-by":"crossref","DOI":"10.1016\/j.preme.2024.100013","article-title":"Bacteria-based bioactive materials for tumor immunotherapy","volume":"1","author":"Li","year":"2024","journal-title":"Precision Med. Eng."},{"key":"10.1016\/j.actbio.2026.07.022_bib0189","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41392-024-02070-1","article-title":"Emerging regulatory mechanisms and functions of biomolecular condensates: implications for therapeutic targets","volume":"10","author":"Jeon","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.actbio.2026.07.022_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.preme.2025.100024","article-title":"Precise CAR-t cell therapy targeting non-cancerous diseases: advances in precision medicine and bioengineering","volume":"2","author":"Zhu","year":"2025","journal-title":"Precision Med. Eng."},{"key":"10.1016\/j.actbio.2026.07.022_bib0191","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41563-021-01057-5","article-title":"Next-generation cancer organoids","volume":"21","author":"LeSavage","year":"2022","journal-title":"Nat. Mater."},{"key":"10.1016\/j.actbio.2026.07.022_bib0192","doi-asserted-by":"crossref","DOI":"10.1016\/j.preme.2025.100045","article-title":"Development of organoids for drug research and tissue regeneration","volume":"2","author":"Sun","year":"2025","journal-title":"Precision Med. Eng."},{"key":"10.1016\/j.actbio.2026.07.022_bib0193","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1016\/j.apsb.2025.04.031","article-title":"Immune organoid for cancer immunotherapy","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.actbio.2026.07.022_bib0194","first-page":"10","article-title":"AI-based multiomics profiling reveals complementary omics contributions to personalized prediction of cardiovascular disease","volume":"17","author":"Luo","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2026.07.022_bib0195","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1136\/gutjnl-2025-337171","article-title":"Shaping the future of postoperative recurrence in crohn's disease: personalised approaches with AI-enabled imaging and multi-omics","volume":"75","author":"Iacucci","year":"2026","journal-title":"Gut"},{"key":"10.1016\/j.actbio.2026.07.022_bib0196","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1039\/D5CS01406A","article-title":"Artificial intelligence-powered nanomedicine","volume":"55","author":"Luo","year":"2026","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.actbio.2026.07.022_bib0197","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70154","article-title":"Triazole-pyrimidine hybrids as EGFR inhibitors via synthesis, in silico, in vitro, and in vivo evaluation as anticancer agents","volume":"86","author":"Dubey","year":"2025","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.actbio.2026.07.022_bib0198","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1142\/S2737416525501005","article-title":"Design and discovery of novel quinazoline derivatives as HER2 inhibitors for targeted cancer therapy","volume":"25","author":"Maity","year":"2026","journal-title":"J. Comput. Biophys. Chem."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706126004678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706126004678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:49:23Z","timestamp":1787053763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706126004678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":198,"alternative-id":["S1742706126004678"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2026.07.022","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging biomaterials deliver heat shock protein 90 inhibitors to enhance therapeutic efficacy in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2026.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}